Table I.
Participant Characteristics
| Characteristic | Placebo (N = 17) | Mometasone (N = 35) | P |
|---|---|---|---|
| Male sex, N(%) | 11 (64%) | 17 (49%) | 0.4 |
| Age (y) | |||
| Mean (SD) | 36 (9.81) | 30 (8.56) | 0.02 |
| Hemoglobin diagnosis | 1.0 | ||
| HbSS | 16 | 34 | |
| Hb Sβ0 thalassemia | 1 | 1 | |
| Medical History | |||
| HU therapy N (%) | 11 (64.7%) | 23 (65.7%) | 1.0 |
| History of eczema | 1 (6%) | 4 (11%) | 1.0 |
| History of allergies | 6 (35%) | 14 (40%) | 0.3 |
| Smoking | 0.8 | ||
| Never, N(%) | 9 (52%) | 22 (63%) | |
| Smoked in past but not now, N(%) | 6 (35%) | 10 (29%) | |
| Current smoker | 2 (12%) | 3 (9%) | |
| Steady state Hemoglobin | |||
| Mean(SD) | 9.01 (1.13) | 8.71 (1.49) | 0.5 |
| Steady State Hemoglobin F % | |||
| Mean (SD) | 10.56 (7.32) | 9.03 (6.56) | 0.5 |
| Spirometry at study entry | |||
| FEV1 % Predicted mean (SD) | 86.67(21.88) | 87.83 (12.90) | 0.9 |
| FVC % Predicted mean (SD) | 87.47 (12.36) | 92.00 (16.08) | 0.3 |
| FEV1/FVC mean (SD) | 80.14 (14.95) | 83.24 (3.56) | 0.4 |
| Positive bronchodilator response* | 0 | 0 | 0.6 |
| Exhaled NO ppb mean (SD) | 15.35 (10.11) | 14.00 (6.27) | |
| Prior ED Utilization (past 12 months) | 0.4 | ||
| 0–5 visits – n (%) | 12 (71%) | 30 (86%) | |
| 6–10 visits – n (%) | 4 (24%) | 4 (11%) | |
| 11–15 visits – n (%) | 1 (6%) | 1 (3%) | |
| Laboratory values at study entry | |||
| Hemoglobin g/dL | |||
| Mean (SD) | 8.92 (1.59) | 8.55 (1.54) | 0.4 |
| WBC count, × 103/μL | |||
| Mean (SD) | 11.84 (4.48) | 10.55 (3.81) | 0.3 |
| Hemoglobin F % | |||
| Mean (SD) | 9.19 (7.27) | 8.52 (6.09) | 0.7 |
| Reticulocyte count % | |||
| Mean (SD) | 7.71 (2.86) | 7.74 (4.03) | 0.97 |
| Lactate dehydrogenase IU/I | |||
| Mean (SD) | 367.60 (207.08) | 440.21 (182.47) | 0.5 |
| sVCAM mg/mL | |||
| Mean (SD) | 2378.9 (987.4) | 2712.7 (1478.8) | 0.4 |
*
Positive bronchodilator response defined as an improvement of greater than 12% in FEV1